Literature DB >> 19073732

Vaccinia virus-mediated inhibition of type I interferon responses is a multifactorial process involving the soluble type I interferon receptor B18 and intracellular components.

Zoe Waibler1, Martina Anzaghe, Theresa Frenz, Astrid Schwantes, Christopher Pöhlmann, Holger Ludwig, Marcos Palomo-Otero, Antonio Alcamí, Gerd Sutter, Ulrich Kalinke.   

Abstract

Poxviruses such as virulent vaccinia virus (VACV) strain Western Reserve encode a broad range of immune modulators that interfere with host responses to infection. Upon more than 570 in vitro passages in chicken embryo fibroblasts (CEF), chorioallantois VACV Ankara (CVA) accumulated mutations that resulted in highly attenuated modified vaccinia virus Ankara (MVA). MVA infection of mice and of dendritic cells (DC) induced significant type I interferon (IFN) responses, whereas infection with VACV alone or in combination with MVA did not. These results implied that VACV expressed an IFN inhibitor(s) that was functionally deleted in MVA. To further characterize the IFN inhibitor(s), infection experiments were carried out with CVA strains isolated after 152 (CVA152) and 386 CEF passages (CVA386). Interestingly, neither CVA152 nor CVA386 induced IFN-alpha, whereas the latter variant did induce IFN-beta. This pattern suggested a consecutive loss of inhibitors during MVA attenuation. Similar to supernatants of VACV- and CVA152-infected DC cultures, recombinantly expressed soluble IFN decoy receptor B18, which is encoded in the VACV genome, inhibited MVA-induced IFN-alpha but not IFN-beta. In the same direction, a B18R-deficient VACV variant triggered only IFN-alpha, confirming B18 as the soluble IFN-alpha inhibitor. Interestingly, VACV infection inhibited IFN responses induced by a multitude of different stimuli, including oligodeoxynucleotides containing CpG motifs, poly(I:C), and vesicular stomatitis virus. Collectively, the data presented show that VACV-mediated IFN inhibition is a multistep process involving secreted factors such as B18 plus intracellular components that cooperate to efficiently shut off systemic IFN-alpha and IFN-beta responses.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19073732      PMCID: PMC2643777          DOI: 10.1128/JVI.01617-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  62 in total

1.  Interferon treatment inhibits early events in vaccinia virus gene expression in infected mice.

Authors:  J R Rodriguez; D Rodriguez; M Esteban
Journal:  Virology       Date:  1991-12       Impact factor: 3.616

Review 2.  Vaccinia virus immune evasion.

Authors:  G L Smith; J A Symons; A Khanna; A Vanderplasschen; A Alcamí
Journal:  Immunol Rev       Date:  1997-10       Impact factor: 12.988

Review 3.  Viral strategies of immune evasion.

Authors:  H L Ploegh
Journal:  Science       Date:  1998-04-10       Impact factor: 47.728

Review 4.  Cytokine receptors encoded by poxviruses: a lesson in cytokine biology.

Authors:  A Alcamí; G L Smith
Journal:  Immunol Today       Date:  1995-10

5.  Vaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species specificity.

Authors:  J A Symons; A Alcamí; G L Smith
Journal:  Cell       Date:  1995-05-19       Impact factor: 41.582

Review 6.  Immune defence in mice lacking type I and/or type II interferon receptors.

Authors:  M F van den Broek; U Müller; S Huang; R M Zinkernagel; M Aguet
Journal:  Immunol Rev       Date:  1995-12       Impact factor: 12.988

7.  Immune response in mice that lack the interferon-gamma receptor.

Authors:  S Huang; W Hendriks; A Althage; S Hemmi; H Bluethmann; R Kamijo; J Vilcek; R M Zinkernagel; M Aguet
Journal:  Science       Date:  1993-03-19       Impact factor: 47.728

8.  Vaccinia virus B18R gene encodes a type I interferon-binding protein that blocks interferon alpha transmembrane signaling.

Authors:  O R Colamonici; P Domanski; S M Sweitzer; A Larner; R M Buller
Journal:  J Biol Chem       Date:  1995-07-07       Impact factor: 5.157

9.  Antiviral defense in mice lacking both alpha/beta and gamma interferon receptors.

Authors:  M F van den Broek; U Müller; S Huang; M Aguet; R M Zinkernagel
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

10.  Functional role of type I and type II interferons in antiviral defense.

Authors:  U Müller; U Steinhoff; L F Reis; S Hemmi; J Pavlovic; R M Zinkernagel; M Aguet
Journal:  Science       Date:  1994-06-24       Impact factor: 47.728

View more
  41 in total

1.  A major role for TLR8 in the recognition of vaccinia viral DNA by murine pDC?

Authors:  Stefan Bauer; Barbara Bathke; Henning Lauterbach; Juliane Pätzold; Ronny Kassub; Christian A Luber; Beatrix Schlatter; Svetlana Hamm; Paul Chaplin; Mark Suter; Hubertus Hochrein
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-02       Impact factor: 11.205

Review 2.  Cytokine-receptor interactions as drug targets.

Authors:  Gideon Schreiber; Mark R Walter
Journal:  Curr Opin Chem Biol       Date:  2010-07-07       Impact factor: 8.822

3.  Treating tumors with a vaccinia virus expressing IFNβ illustrates the complex relationships between oncolytic ability and immunogenicity.

Authors:  Liang-Chuan S Wang; Rachel C Lynn; Guanjun Cheng; Edward Alexander; Veena Kapoor; Edmund K Moon; Jing Sun; Zvi G Fridlender; Stuart N Isaacs; Stephen H Thorne; Steven M Albelda
Journal:  Mol Ther       Date:  2011-10-18       Impact factor: 11.454

Review 4.  Viruses as vaccine vectors for infectious diseases and cancer.

Authors:  Simon J Draper; Jonathan L Heeney
Journal:  Nat Rev Microbiol       Date:  2010-01       Impact factor: 60.633

5.  MyD88-dependent immunity to a natural model of vaccinia virus infection does not involve Toll-like receptor 2.

Authors:  Michael L Davies; Janet J Sei; Nicholas A Siciliano; Ren-Huan Xu; Felicia Roscoe; Luis J Sigal; Laurence C Eisenlohr; Christopher C Norbury
Journal:  J Virol       Date:  2014-01-08       Impact factor: 5.103

6.  Interference with SAMHD1 Restores Late Gene Expression of Modified Vaccinia Virus Ankara in Human Dendritic Cells and Abrogates Type I Interferon Expression.

Authors:  Katja Sliva; Judith Martin; Christine von Rhein; Tobias Herrmann; Anastasia Weyrich; Masako Toda; Barbara S Schnierle
Journal:  J Virol       Date:  2019-10-29       Impact factor: 5.103

7.  The ORF4b-encoded accessory proteins of Middle East respiratory syndrome coronavirus and two related bat coronaviruses localize to the nucleus and inhibit innate immune signalling.

Authors:  Krystal L Matthews; Christopher M Coleman; Yvonne van der Meer; Eric J Snijder; Matthew B Frieman
Journal:  J Gen Virol       Date:  2014-01-17       Impact factor: 3.891

8.  Type I IFN blockade uncouples immunotherapy-induced antitumor immunity and autoimmune toxicity.

Authors:  Scott R Walsh; Donald Bastin; Lan Chen; Andrew Nguyen; Christopher J Storbeck; Charles Lefebvre; David Stojdl; Jonathan L Bramson; John C Bell; Yonghong Wan
Journal:  J Clin Invest       Date:  2018-12-18       Impact factor: 14.808

Review 9.  Subversion of cytokine networks by virally encoded decoy receptors.

Authors:  Megan L Epperson; Chung A Lee; Daved H Fremont
Journal:  Immunol Rev       Date:  2012-11       Impact factor: 12.988

10.  The highly virulent variola and monkeypox viruses express secreted inhibitors of type I interferon.

Authors:  María del Mar Fernández de Marco; Alí Alejo; Paul Hudson; Inger K Damon; Antonio Alcami
Journal:  FASEB J       Date:  2009-12-17       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.